Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.21
PRGO's Cash-to-Debt is ranked lower than
85% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. PRGO: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
PRGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.12 Max: 109
Current: 0.21
0
109
Equity-to-Asset 0.52
PRGO's Equity-to-Asset is ranked lower than
67% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. PRGO: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
PRGO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.57 Max: 0.75
Current: 0.52
0.34
0.75
Debt-to-Equity 0.60
PRGO's Debt-to-Equity is ranked lower than
70% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. PRGO: 0.60 )
Ranked among companies with meaningful Debt-to-Equity only.
PRGO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.38 Max: 1.23
Current: 0.6
0
1.23
Debt-to-EBITDA -3.33
PRGO's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. PRGO: -3.33 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PRGO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.76  Med: 3.12 Max: 5.8
Current: -3.33
-3.76
5.8
Piotroski F-Score: 4
Altman Z-Score: 0.38
Beneish M-Score: -3.36
WACC vs ROIC
4.32%
-11.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -34.17
PRGO's Operating Margin % is ranked lower than
82% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. PRGO: -34.17 )
Ranked among companies with meaningful Operating Margin % only.
PRGO' s Operating Margin % Range Over the Past 10 Years
Min: -37.87  Med: 14.71 Max: 19.18
Current: -34.17
-37.87
19.18
Net Margin % -79.83
PRGO's Net Margin % is ranked lower than
86% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. PRGO: -79.83 )
Ranked among companies with meaningful Net Margin % only.
PRGO' s Net Margin % Range Over the Past 10 Years
Min: -79.83  Med: 7.52 Max: 12.66
Current: -79.83
-79.83
12.66
ROE % -52.76
PRGO's ROE % is ranked lower than
86% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. PRGO: -52.76 )
Ranked among companies with meaningful ROE % only.
PRGO' s ROE % Range Over the Past 10 Years
Min: -52.76  Med: 15.81 Max: 25.88
Current: -52.76
-52.76
25.88
ROA % -25.25
PRGO's ROA % is ranked lower than
82% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. PRGO: -25.25 )
Ranked among companies with meaningful ROA % only.
PRGO' s ROA % Range Over the Past 10 Years
Min: -25.25  Med: 5.89 Max: 11.14
Current: -25.25
-25.25
11.14
ROC (Joel Greenblatt) % -92.87
PRGO's ROC (Joel Greenblatt) % is ranked lower than
81% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. PRGO: -92.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRGO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -112.02  Med: 36.25 Max: 53.06
Current: -92.87
-112.02
53.06
3-Year Revenue Growth Rate -0.50
PRGO's 3-Year Revenue Growth Rate is ranked lower than
71% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PRGO: -0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRGO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.5  Med: 7.45 Max: 17.5
Current: -0.5
-5.5
17.5
GuruFocus has detected 4 Warning Signs with Perrigo Co PLC PRGO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRGO's 30-Y Financials

Financials (Next Earnings Date: 2017-11-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PRGO Guru Trades in Q3 2016

Jim Simons 285,308 sh (New)
Ken Fisher 529,719 sh (+55.81%)
Manning & Napier Advisors, Inc 2,608,714 sh (+15.24%)
Ruane Cunniff 1,479,353 sh (+12.43%)
Robert Bruce 9,926 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
David Einhorn Sold Out
John Paulson Sold Out
Jana Partners Sold Out
Jerome Dodson Sold Out
Murray Stahl 10,302 sh (-3.08%)
» More
Q4 2016

PRGO Guru Trades in Q4 2016

George Soros 5,400 sh (New)
Joel Greenblatt 9,138 sh (New)
Paul Tudor Jones 4,724 sh (New)
First Pacific Advisors 1,297,550 sh (New)
Jim Simons 628,508 sh (+120.29%)
Robert Bruce 9,926 sh (unchged)
Manning & Napier Advisors, Inc 2,571,194 sh (-1.44%)
Murray Stahl 10,043 sh (-2.51%)
Ken Fisher 514,718 sh (-2.83%)
Ruane Cunniff 1,315,276 sh (-11.09%)
» More
Q1 2017

PRGO Guru Trades in Q1 2017

David Einhorn 1,700,000 sh (New)
Jeremy Grantham 165,592 sh (New)
Paul Tudor Jones 13,281 sh (+181.14%)
Murray Stahl 11,262 sh (+12.14%)
First Eagle Investment 4,800 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Jeremy Grantham 400,000 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
First Pacific Advisors Sold Out
Manning & Napier Advisors, Inc 2,420,836 sh (-5.85%)
Ken Fisher 481,172 sh (-6.52%)
Ruane Cunniff 617,478 sh (-53.05%)
» More
Q2 2017

PRGO Guru Trades in Q2 2017

First Eagle Investment 34,200 sh (New)
Jim Simons 362,508 sh (New)
Joel Greenblatt 330,376 sh (New)
David Einhorn 2,527,000 sh (+48.65%)
Manning & Napier Advisors, Inc 2,586,068 sh (+6.83%)
First Eagle Investment 4,800 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Jeremy Grantham 400,000 sh (unchged)
Ruane Cunniff Sold Out
Murray Stahl 10,957 sh (-2.71%)
Ken Fisher 465,952 sh (-3.16%)
Jeremy Grantham 45,199 sh (-72.70%)
Paul Tudor Jones 3,624 sh (-72.71%)
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Einhorn 2017-06-30 Add 48.65%1.01%$66.14 - $76.5 $ 88.1323%2,527,000
Ken Fisher 2017-06-30 Reduce -3.16%$66.14 - $76.5 $ 88.1323%465,952
Joel Greenblatt 2017-06-30 New Buy0.35%$66.14 - $76.5 $ 88.1323%330,376
First Eagle Investment 2017-06-30 New Buy0.01%$66.14 - $76.5 $ 88.1323%34,200
Ruane Cunniff 2017-06-30 Sold Out 0.39%$66.14 - $76.5 $ 88.1323%0
David Einhorn 2017-03-31 New Buy1.57%$66.39 - $87.23 $ 88.1316%1,700,000
Ruane Cunniff 2017-03-31 Reduce -53.05%0.55%$66.39 - $87.23 $ 88.1316%617,478
Ken Fisher 2017-03-31 Reduce -6.52%0.01%$66.39 - $87.23 $ 88.1316%481,172
George Soros 2017-03-31 Sold Out 0.01%$66.39 - $87.23 $ 88.1316%0
Joel Greenblatt 2017-03-31 Sold Out 0.01%$66.39 - $87.23 $ 88.1316%0
Ruane Cunniff 2016-12-31 Reduce -11.09%0.14%$79.95 - $96.73 $ 88.132%1,315,276
Ken Fisher 2016-12-31 Reduce -2.83%$79.95 - $96.73 $ 88.132%514,718
Joel Greenblatt 2016-12-31 New Buy0.01%$79.95 - $96.73 $ 88.132%9,138
George Soros 2016-12-31 New Buy0.01%$79.95 - $96.73 $ 88.132%5,400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SHSE:600196, OCSE:LUN, XPAR:IPN, TSE:4508, JSE:APN, SZSE:000538, TSE:4523, SHSE:600518, BOM:532321, HKSE:03320, XSWX:VIFN, NAS:MYL, SZSE:000963, SHSE:603858, BOM:500257, TSE:4507, SHSE:600085, BSP:HYPE3, OHEL:ORNBV, SZSE:300122 » details
Traded in other countries:PIG.Germany, PRGO.Israel,
Headquarter Location:Ireland
Perrigo Co PLC is a healthcare company providing branded OTC products throughout Europe and the USA. It sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

Perrigo is the largest store-brand over-the-counter pharmaceutical and infant formula manufacturer. The company operates four segments: consumer health care, branded consumer healthcare, prescription pharmaceuticals, and active pharmaceutical ingredients. In the U.S., Perrigo sells about 2,100 products with 9,000 stock-keeping units. Following the acquisition of Omega Pharma, approximately 25% of the company's revenue comes from outside the U.S.

Guru Investment Theses on Perrigo Co PLC

David Einhorn Comments on Perrigo - May 17, 2017

Perrigo (NYSE:PRGO) is the largest manufacturer of private label over -the-counter (OTC) pharmaceutical products for U.S. retailers and pharmacy chains. Over the past decade the company acquired other business lines, including a portfolio of European OTC brands (Omega), a generics pharmaceutical business, and a royalty stream on a large multiple sclerosis drug that has since been divested. In November 2015, shareholders rejected a hostile takeover offer from Mylan worth $175 per share after the then-CEO laid out ambitious standalone earnings targets. Unfortunately for shareholders, these targets proved far too optimistic and the CEO ultimately departed. After several large guidance cuts, we believe the new management team has now set achievable earnings forecasts. Omega’s business suffered from large restructuring expenses last year that should not recur and has additional margin upside as it streamlines its product portfolio. The company also has a dominant market position in its core U.S. OTC business and should continue to grow profits in this segment. We believe the U.S. OTC business and Omega have profit and growth characteristics similar to consumer products businesses, which trade at healthy multiples due to the stability of their cash flows. We purchased PRGO at an average price of $68.81 per share or 11x our estimate of 2019 earnings. PRGO shares ended the quarter at $66.39.





  • From Einhorn's first-quarter 2017 shareholder commentary.


Check out David Einhorn latest stock trades

Jerome Dodson Comments on Perrigo - Jan 25, 2017

The Fund’s weakest performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock plummeted 42.5%, from $144.70 to $83.23, cutting 103 basis points from the Fund’s return. The shares sank in April after longtime CEO Joe Papa resigned to become the CEO of Valeant Pharmaceuticals. The stock continued to move lower throughout the year as the company cut its earnings guidance three times, from nearly $10 per share to just $7. The business underperformed due to declining prescription generic drug prices and soft growth from Omega, Perrigo’s European business. We sold our position during the year due to our concerns that the prescription generic pricing environment would get worse and that it would take longer than expected to fix Omega.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Perrigo - Nov 01, 2016

We sold Perrigo (NYSE:PRGO), a producer of store-brand generic drugs, due to our concerns that the generic pricing environment would get worse and that it would take longer than expected to improve the company’s European platform. Additionally, we sold credit card issuer American Express, because we believe its moat is narrowing. Intense competition for the company’s affluent cardholders is pushing up rewards costs and marketing expenses, thereby lowering the company’s return on capital.

From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third-quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

Keeley Funds Comment on Perrigo Co. - Aug 03, 2016

Perrigo Co. (NYSE:PRGO) was the Fund’s leading detractor this quarter. The stock price dropped over 22% and cost the Fund 62 basis points in performance. The company focuses on the production of over-the-counter consumer goods and specialty pharmaceutical products. The stock price dropped after the former CEO departed to join Valeant Pharmaceuticals and the Board of Directors named a new CEO. The new CEO promptly reduced guidance, causing an increase in skepticism about management’s ability to integrate a recent European acquisition.



From Keeley Funds' All Cap Value Fund second quarter commentary.



Check out John Keeley latest stock trades

Jerome Dodson Comments on Perrigo - Jul 26, 2016

Four companies each contributed 20 basis points or more to the Fund’s return this quarter, but six subtracted 20 basis points or more from the return. Our worst performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock sank 29.1% from $127.93 to $90.67, cutting 69 basis points from the Fund’s return. Shares plummeted in April after longtime CEO Joe Papa resigned to become the CEO at Valeant Pharmaceuticals, and Perrigo lowered its 2016 guidance for the second time this year. The business has underperformed due to declining generic drug prices and weak growth from Omega, Perrigo’s European business. While we think John Hendrickson, Perrigo’s new CEO, is the right person for the job given his strong operational background, we’re continuing to monitor the drug pricing environment.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

David Rolfe Comments on Perrigo - Jul 13, 2016

During the quarter, a surprising decline in Perrigo (NYSE:PRGO)’s normally staid generic prescription (Rx) business had the Company reduce full-year guidance by almost 15% in a late-April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of disconcerting data points, we decided it prudent to liquidate our Perrigo stake.

We think that, at its core, Perrigo’s U.S. private label over-the-counter (OTC) business is intrinsically attractive, with nearly 70% market share and long-tailed revenue streams similar to that of a consumer staple. Private-label OTC was about 50% of the Company’s calendar 2015 revenue, and nearly 40% of consolidated operating profitability.

Another third of Perrigo’s profits was derived from their generic Rx business which we believed, until recently, was relatively defensible. We had seen that Perrigo’s strategy in generic Rx was to target drugs that had small addressable markets (often less than $50 million per year sales), but a good probability of eventually becoming approved for OTC. We hypothesized that Perrigo’s rivals were slow to copy Perrigo generic drugs either because the addressable market was not big enough, and/or because margins on OTC are dramatically lower than Rx, particularly for sub-scale OTC manufacturers. (Private-label OTC manufacturing, marketing, and distribution support capabilities are substantially different from prescription). In other words, we saw Perrigo’s substantial scale in private-label OTC as enabling the Company to realize unique economics in other parts of their business, namely generic Rx. Therefore, it was surprising to us when the Company cut its own guidance for this unit by double-digits and then offered little in the way of an outlook, despite having provided a steady outlook just a few months ago.

Further, Perrigo’s relatively new BCH platform continued to underperform. The company expended almost $4.5 billion in shareholder capital to acquire BCH’s core asset, Omega Pharmaceutical, in early 2015. We think this business will be ineffective as a growth platform, despite management’s previous optimism. The Company has commented that the highly entrepreneurial culture of Omega has made it difficult to scale this business through further bolt-on acquisitions. The scaling of acquisitions has been a key component of Perrigo’s long-term growth strategy, so we would not be surprised if there are more examples of unrealized value- destruction embedded in the Omega acquisition.

Finally, Mr. Joe Papa, now former CEO of Perrigo, abruptly exited the Company in late April.
 Mr. Papa’s exit came after having spent countless hours and money, with the Board of Directors’ encouragement and unanimous approval, fending off Mylan’s hostile bid on the basis of the following: Perrigo’s stock being undervalued, Mylan’s poor corporate governance record, and the risk of dis-synergies. We now find shares trading at about half the supposedly undervalued bid price; Mr. Papa’s departure to run a company with one of the worst corporate governance track records around, dis-synergies from the Omega acquisition; and a materially weakened generic Rx franchise. Importantly, we think that execution missteps are expected over the long term and therefore manageable (if only because we can handicap those hiccups by building in a valuation cushion). However, we do not invest in Companies that are not forthcoming with their investor base. We question the credibility of Perrigo’s remaining management team, as well as the Board of Directors. In our experience, fortunately, this has been thankfully rare.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Perrigo - Jul 13, 2016

Perrigo (NYSE:PRGO) detracted –1.04% from the composite's absolute performance. A surprising decline in Perrigo’s normally staid generic prescription (Rx) business had the company reduce full-year guidance by almost 15% in a late April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of data points, we decided it prudent to liquidate our Perrigo stake.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Perrigo - Apr 15, 2016

Perrigo (NYSE:PRGO)

Perrigo was a bottom performance contributor in the quarter, as the company reported a miss in its Branded Consumer Healthcare (BCH) segment. Management attributed the miss to execution issues and dedicated themselves to solving these problems over the coming quarters. We are willing to be patient; in the meantime, as we think that Perrigo’s core, private label OTC business is unique and should remain a healthy and sustainable source of internal capital.

Perrigo’s BCH segment was established after closing on the acquisition of Omega Pharma (Belgium) in March 2015. Mylan’s hostile bid for Perrigo was launched a few weeks later, and did not conclude until mid-November. We think that Perrigo’s BCH execution issues are understandable (if not predictable), as management was admittedly distracted by fending off Mylan’s hostile bid for the Company during much of 2015. Over the next several quarters, we expect BCH to post improved results, as it is better integrated with Perrigo’s corporate planning cycle.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners 1st Quarter 2016 Client Letter.

Check out David Rolfe latest stock trades

Baron Funds Comments on Perrigo Company Plc - Jan 26, 2016

We re-established an investment in Perrigo Company Plc (NYSE:PRGO) during the quarter. Perrigo is a leading global over-the-counter (OTC) consumer goods and specialty pharmaceutical manufacturer. The company is the world’s largest manufacturer of store brand OTC health care products (such as store brand ibuprofen, the active ingredient in Advil), which are sold in virtually all leading U.S. drug retailers, including Walgreens and CVS. We previously owned Perrigo in the Fund. In early 2015, the company became the subject of a hostile takeover bid by Mylan N.V., a large manufacturer of generic pharmaceuticals. After Perrigo shareholders rejected Mylan’s proposal, Perrigo’s stock fell to a price that we believed was attractive in light of the company’s growth potential, competitive advantages and impressive management team.



We think Perrigo can generate sustainable mid-to-high single digit organic revenue growth, driven by a trend favoring store brand OTC drugs over national brands. Perrigo management estimates its business saves consumers more than $7.5 billion annually in their health care spending ($1 savings for every person in the world). This is because store brand OTC drugs are comparable in quality and effectiveness to the national brands but cost significantly less. Store brand OTC drugs also generate higher gross margins for retailers.



We think Perrigo’s business should also benefit as more prescription drugs move to OTC status. This trend is being driven by branded drug manufacturers seeking to capture ongoing product sales after the products lose patent protection. Perrigo has dominant market share in the store brand OTC drug business. We believe the company’s competitive advantages include long-standing customer relationships, low cost manufacturing and an ability to mass customize thousands of products and support retailers in marketing their store brands.



Perrigo’s management team has a strong record of creating shareholder value. They have a disciplined approach to deploying capital with a focus on meeting return on invested capital hurdles. We think management will continue to pursue acquisitions which should add to the company’s growth. These acquisitions could include products that Perrigo could add to its distribution network at high incremental margin, products in new categories, or companies in new geographies. In addition, in its defense against the Mylan hostile takeover attempt, Perrigo management committed to several shareholder value creating initiatives that are expected to add to earnings over the next few years.



From Baron Funds' Baron Asset Fund commentary for fourth quarter 2015.



Check out Ron Baron latest stock trades

Wedgewood Partners Comments on Perrigo - Jan 18, 2016

Perrigo (NYSE:PRGO) is another position that we added to during the quarter. We had previously pared positions at materially higher levels after Mylan’s hostile bid for Perrigo became public information. Upon the recent expiration of the hostile offer, shares traded down to valuation levels not seen since 2008-2009, at which time we added back to our position. Management has guided to solid future growth, driven by the Company’s leading position in manufacturing and distributing private label over-the-counter (OTC) drugs to U.S. retailers, as well as its relatively new and rapidly expanding European OTC platform.



From Wedgewood Partners' fourth quarter 2015 client letter.



Check out David Rolfe latest stock trades

Top Ranked Articles about Perrigo Co PLC

Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent Of Nexium® 24HR Capsules
Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Exalgo® 32mg Extended Release Tablets
Perrigo Announces Tentative FDA Approval For The Generic Version Of Acanya® Gel
Perrigo Company To Present At Upcoming Investor Conferences
Perrigo Announces Final FDA Approval And Settlement For The Store Brand OTC Equivalent Of Nexium® 24HR Capsules
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog® II Cream
Kohl's, Dillard's, Live Nation Entertainment Moving Despite International Tensions Stocks moving on earnings reports
The U.S. stock index futures were losing ground in premarket trading Thursday while tensions continue between North Korea and the U.S. With the dollar up against most of its peers, the Dow Jones Industrial Average, the S&P 500 and the Nasdaq Composite are all in red while gold trades at a two-month high. The yield on 10-year U.S. Treasury Notes is 2.226%. Read more...
Perrigo Company plc Announces Quarterly Dividend
Perrigo Announces Tentative FDA Approval For Generic Version Of Mirvaso® Gel
Perrigo Announces The Launch Of The AB Rated Generic Version Of Transderm Scop® 1.5 mg

Ratios

vs
industry
vs
history
Forward PE Ratio 17.33
PRGO's Forward PE Ratio is ranked higher than
57% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. PRGO: 17.33 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.08
PRGO's PB Ratio is ranked higher than
65% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. PRGO: 2.08 )
Ranked among companies with meaningful PB Ratio only.
PRGO' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.03 Max: 5.96
Current: 2.08
1.27
5.96
PS Ratio 2.60
PRGO's PS Ratio is ranked higher than
54% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. PRGO: 2.60 )
Ranked among companies with meaningful PS Ratio only.
PRGO' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.6 Max: 6.68
Current: 2.6
0.95
6.68
Price-to-Free-Cash-Flow 20.21
PRGO's Price-to-Free-Cash-Flow is ranked higher than
62% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. PRGO: 20.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PRGO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.63  Med: 27.49 Max: 84.98
Current: 20.21
10.63
84.98
Price-to-Operating-Cash-Flow 17.76
PRGO's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. PRGO: 17.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PRGO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.68  Med: 19.38 Max: 36.66
Current: 17.76
8.68
36.66
EV-to-EBIT -9.34
PRGO's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. PRGO: -9.34 )
Ranked among companies with meaningful EV-to-EBIT only.
PRGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.8  Med: 19.8 Max: 1728.4
Current: -9.34
-11.8
1728.4
EV-to-EBITDA -14.02
PRGO's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. PRGO: -14.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.6  Med: 15.4 Max: 56.2
Current: -14.02
-20.6
56.2
EV-to-Revenue 3.19
PRGO's EV-to-Revenue is ranked higher than
50% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. PRGO: 3.19 )
Ranked among companies with meaningful EV-to-Revenue only.
PRGO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 3.3 Max: 7.9
Current: 3.19
1.3
7.9
Current Ratio 1.73
PRGO's Current Ratio is ranked lower than
65% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. PRGO: 1.73 )
Ranked among companies with meaningful Current Ratio only.
PRGO' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 2.37 Max: 4.05
Current: 1.73
1.1
4.05
Quick Ratio 1.23
PRGO's Quick Ratio is ranked lower than
67% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. PRGO: 1.23 )
Ranked among companies with meaningful Quick Ratio only.
PRGO' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.2 Max: 3.56
Current: 1.23
0.76
3.56
Days Inventory 104.90
PRGO's Days Inventory is ranked higher than
58% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. PRGO: 104.90 )
Ranked among companies with meaningful Days Inventory only.
PRGO' s Days Inventory Range Over the Past 10 Years
Min: 92.5  Med: 99.73 Max: 110.74
Current: 104.9
92.5
110.74
Days Sales Outstanding 80.25
PRGO's Days Sales Outstanding is ranked lower than
56% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. PRGO: 80.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.9  Med: 67.15 Max: 104.43
Current: 80.25
57.9
104.43
Days Payable 60.15
PRGO's Days Payable is ranked lower than
57% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. PRGO: 60.15 )
Ranked among companies with meaningful Days Payable only.
PRGO' s Days Payable Range Over the Past 10 Years
Min: 53.32  Med: 62.91 Max: 100.23
Current: 60.15
53.32
100.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.71
PRGO's Dividend Yield % is ranked lower than
78% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. PRGO: 0.71 )
Ranked among companies with meaningful Dividend Yield % only.
PRGO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.4 Max: 1.09
Current: 0.71
0.22
1.09
3-Year Dividend Growth Rate 18.30
PRGO's 3-Year Dividend Growth Rate is ranked higher than
73% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. PRGO: 18.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PRGO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4 Max: 49.8
Current: 18.3
0
49.8
Forward Dividend Yield % 0.72
PRGO's Forward Dividend Yield % is ranked lower than
78% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. PRGO: 0.72 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.49
PRGO's 5-Year Yield-on-Cost % is ranked lower than
61% of the 849 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. PRGO: 1.49 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PRGO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.45  Med: 0.83 Max: 2.25
Current: 1.49
0.45
2.25
3-Year Average Share Buyback Ratio -15.10
PRGO's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. PRGO: -15.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: 0.2 Max: 1.9
Current: -15.1
-16.1
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.30
PRGO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. PRGO: 1.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PRGO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.64 Max: 3.82
Current: 1.3
0.98
3.82
Price-to-Median-PS-Value 1.00
PRGO's Price-to-Median-PS-Value is ranked higher than
59% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. PRGO: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRGO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.59 Max: 2.35
Current: 1
0.2
2.35
Earnings Yield (Greenblatt) % -10.72
PRGO's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. PRGO: -10.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRGO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.2  Med: 4.8 Max: 8.5
Current: -10.72
-13.2
8.5
Forward Rate of Return (Yacktman) % -1.41
PRGO's Forward Rate of Return (Yacktman) % is ranked lower than
72% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. PRGO: -1.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PRGO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.9  Med: 9.9 Max: 35.8
Current: -1.41
-1.9
35.8

More Statistics

Revenue (TTM) (Mil) $4,848.30
EPS (TTM) $ -27.02
Beta0.72
Short Percentage of Float8.57%
52-Week Range $63.68 - 92.64
Shares Outstanding (Mil)142.61

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 4,821 4,930 5,037 5,123
EPS ($) 4.56 5.17 5.52 5.72
EPS without NRI ($) 4.56 5.17 5.52 5.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.97%
Dividends per Share ($) 0.40 0.42 0.58 0.87

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}